Enrollment is complete at 540 participants in START, a randomized, placebo-controlled Phase 2 trial of zervimesine (CT1812) in mild cognitive impairment or early Alzheimer’s disease. Approximately 15% of randomized participants are on background monoclonal antibody therapy with lecanemab or donanemab. Participants will receive 18 months of once-daily oral treatment, with efficacy assessed on CDR-SB and ADAS-Cog alongside biomarker and safety measures.
The core development is straightforward: Cognition Therapeutics, working with the NIA-funded Alzheimer’s Clinical Trials Consortium, has filled the study and anticipates topline analysis after all participants complete 18 months of therapy. The design requires evidence of elevated amyloid by PET or CSF at baseline, but does not incorporate serial imaging for safety monitoring, reflecting expectations that zervimesine’s safety profile should not increase ARIA risk. The trial was initiated post-Leqembi approval and deliberately permits stable background anti-amyloid therapy, positioning START to read on both monotherapy and adjunctive settings. The program is substantially de-risked operationally by an $81 million NIA grant and the use of 35 academic sites with Alzheimer’s trial expertise.
Strategically, this is an add-and-expand play rather than an anti-amyloid challenge. Allowing mAb background treatment acknowledges the new standard of care and tests whether a mechanistically distinct small molecule can layer benefit without an additive safety burden or operational complexity. It also opportunistically broadens the addressable population to include patients who cannot access or tolerate mAbs, while keeping the door open to combination use. The late-cycle enrollment surge suggests the academic network and real-world demand for non-infusional options are working in Cognition’s favor. The cost-sharing with federal funding also buys time for a longer, outcomes-focused study without the cash burn typical for 18-month Alzheimer’s trials.
For sites, the design cuts both ways. Screening still requires amyloid confirmation, which taxes imaging and CSF capacity, but the absence of routine MRI safety monitoring and the oral regimen simplifies ongoing visit burden compared to infusion-based therapies. The allowance of background mAbs adds scheduling and pharmacovigilance complexity—especially for tracking ARIA events from the antibody regimen—but more closely mirrors current clinical practice and may have helped recruitment. CROs have less front-line visibility given ACTC’s footprint, but vendors supporting imaging reads, eConsent, and long-horizon retention will be central in a study where attrition can erase signal. Sponsors watching combination logic in Alzheimer’s will see START as an early real-world test of adjunctive design choices, including stratification by background therapy and the feasibility of maintaining statistical power when only about 15% of participants are on concomitant mAbs.
The next inflection hinges on three readouts: a clinically meaningful separation on CDR-SB, consistency across key subgroups (especially those on lecanemab or donanemab), and confirmation of a benign safety profile in a combination setting. With last-patient-in now achieved and 18 months of treatment required, a practical window for topline data lands in 2027, assuming typical data lock and analysis timelines. The chief risks are heterogeneity diluting effect size, underpowered interaction analyses for the mAb subgroup, and retention over an 18-month horizon. If the signal is durable and clean, expect a Phase 3 built around stratified or dedicated combination cohorts and a tighter operational model that blends academic and community sites to scale. Watch for protocol amendments that harden subgroup hypotheses, biomarker-correlated outcomes that support regulatory dialogue, and any operational moves to pre-secure MRI and PET capacity in anticipation of pivotal scale-up.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
